LRCX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lam Research Corp (LRCX) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has shown strong financial performance in its latest quarter, the technical indicators and trading trends do not suggest an immediate entry point. Additionally, insider selling, cautious congressional trading activity, and a recent downgrade from analysts raise concerns. It is recommended to monitor the stock for a better entry point or consider alternative investments.
The MACD histogram is negative (-0.817) and contracting, indicating bearish momentum. RSI is neutral at 49.393, and moving averages are converging, showing no clear trend. The stock is trading below the pivot level of 220.358, with support at 204.02 and resistance at 236.696. Overall, the technical indicators suggest a lack of strong bullish momentum.
Strong financial performance in Q2 2026 with revenue up 22.14% YoY, net income up 33.83% YoY, and EPS up 36.96% YoY.
Analysts from BofA, JPMorgan, and others have raised price targets recently, citing strong growth prospects in wafer fab equipment and AI-driven demand.
Insider selling has increased by 175.61% over the last month.
Congress members have sold $1.5M to $5.0M worth of LRCX stock in the last 90 days, indicating caution.
Erste Group downgraded the stock to Hold due to supply chain risks and potential margin pressure.
The stock has experienced a pre-market decline of -5.44% and regular market decline of -1.61%, reflecting bearish sentiment.
In Q2 2026, Lam Research reported revenue of $5.34 billion, up 22.14% YoY. Net income increased to $1.59 billion, up 33.83% YoY. EPS rose to $1.26, up 36.96% YoY. Gross margin improved to 49.6%, up 4.71% YoY, showcasing strong growth trends.
Analyst sentiment is mixed. While several analysts have raised price targets (e.g., JPMorgan to $300, Cantor Fitzgerald to $320), Erste Group recently downgraded the stock to Hold due to supply chain risks. The overall analyst rating leans towards cautious optimism with some concerns about margin pressure and supply chain dependencies.
